1 / 38

Mycobacteriosis

Mycobacteriosis. Clinical correlations. Mycobacteria. Tuberculosis Leprosy (Hansen Disease) BCG hypersensitivity and infection MOTT AIDS related disseminated MAC Immune reconstitution disease. Mycobacteria. All species resist decoloration, i.e. acid fast

ganesa
Télécharger la présentation

Mycobacteriosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mycobacteriosis Clinical correlations

  2. Mycobacteria • Tuberculosis • Leprosy (Hansen Disease) • BCG hypersensitivity and infection • MOTT • AIDS related disseminated MAC • Immune reconstitution disease

  3. Mycobacteria • All species resist decoloration, i.e. acid fast • All cause granulomatous inflammation • All are more common and/or more severe with cell mediated immune dysfunction • Delayed diagnosis if not specifically sought • Only TB spread person to person

  4. When to suspect Mycobacterial disease • Cavitary, reticulonodular or tree-in-bud pattern on CXR • Underlying structural lung disease* • Cellular immune dysfunction • Subacute or chronic fever, sweats or weight loss, esp. along with CBC abnormality • Any unexplained respiratory symptom/sign in patient with HIV • Cosmetic, plastics esp. breast, or bioprosthetic valve surgery • Granulomatous inflammation * May coexist with other active or inactive lung process

  5. Dx of Mycobacteria • Smear- acid fast stains (Kinyoun, auramine) – rare false positives • Culture – all species other than M.tb and M. leprae must be correlated clinically • PCR – currently only for interpretation respiratory secretion: smear (+) and PCR (+) means TB, smear (+) but PCR (-) means MOTT, smear (-) but PCR (+) means TB • Histology – granulomatous inflammation narrows differential greatly even if stains (-) for AFB

  6. Mycobacterium leprae • Unique infection able to manifest full spectrum from nearly absent to intense granulomatous immune response • Temperate climates worldwide; La., Ark., Tx., Miss. in USA • Not grown in vitro • Respiratory tract entry, seeks cooler areas • Infects schwann cells causing neuropathy

  7. Histology of Leprosy

  8. Acid-Fast Stain: M. leprae

  9. MOTT • Over 100 species, most of little, no or unknown virulence • Similar to TB in histology and staining, trained technicians can distinguish • All can be normal flora except M.kansasii • None person to person • Diagnosis requires more than simply recovering from non-sterile specimen

  10. MOTT Classification • Growth-rate /morphologic system obsolete • Clinically useful to classify by host, organ system (pulmonary vs. lymphatic, cutaneous, disseminated) • Treatment varies greatly with species

  11. MOTT Risk Factors • Structural lung disease (MAC, kansasii,) • Trauma/surgical (M.marinum, rapid growers) • Cellular immune defect (rapid growers, MAC) • Gamma interferon/IL-12 defect • AIDS (MAC, rapid growers, genevensa, hemophilum) • Recurrent aspiration, achalasia (MAC, rapid growers) • Fish tank (M.marinum) • Reptiles ( M chelonei) • Children – Scrofula (M. scrofula, MAC) • Hot-Tubs – Hypersensitivity pneumonitis (MAC)

  12. TABLE 4 Characteristics of patients with nontuberculous mycobacteria pulmonary infections MAC M.xenopi M. kansasii RGM/non-CF Subjects n 125 66 34 16 Underlying conditions Pre-existing pulmonary disease 89 (71.2) 28 (42.4) 7 (20.6) 8 (50) Previous M. tuberculosis 35 (28) 17 (25.8) 9 (26.5) 3 (18.7) Immunosupression/transplantation 34 (27.7) 17 (25.8) 5 (14.7) 1 (6.2) None/anorexia 14 (11.2) 18 (27.3) 15 (44.1) 4 (25) Radiographic abnormalities Infiltrates 46 (36.8) 1 (31.8) 12 (35.3) 8 (50) Nodules 28 (22.4) 21 (31.8) 10 (29.4) 3 (18.7) Cavitation 13 (10.4) 11 (16.7) 13 (38.2) 1 (6.2) Nonspecific 4 (35.2) 19 (28.8) 4 (11.7) 7 (43.7) No symptoms 35 (28) 22 (33.3) 10 (29.4) 0 (0) Data are presented as n, mean (range) or n (%), unless otherwise stated. MAC: Mycobacterium avium-intracellulare complex; M. xenopi: Mycobacterium xenopi; M. Adapted from Dailloux et.al. Eur.Respir.J.,2006;28:1211

  13. AIDS related MAC • CD4 less than 70 • Hectic chronic fever, GI complaints, esp. with very high alkaline phosphatase or severe anemia • Blood culture slow, insensitive; other secretions not specific • Can be pulmonary like with COPD • Antibiotics without antiretrovirals often insufficient

  14. MAC • M. avium complex; includes M. intracellulare, other clinically insignificant ones • By far main MOTT in AIDS • 4 types in relatively competent hosts: 1) fibrocavitary – COPD, etc. 2) fibronodular –older women, collagen defect* 3) cystic fibrosis 4) hypersensitivity (hot tub) pneumonitis * Presumed by assoc. with mitral valve prolapse, scoliosis,joint hypermobility,pectus excavatum

  15. Fibronodular MAC with bronchiectasis

  16. Tree–in–Bud Appearance of Mycobacterial Pneumonitis

  17. Rx of MOTT • Very little correlation or predictive data from susceptibilty testing except for: M.kansasii - rifampin MAC – clarithromycin M.chelonei, fortuitum, abscessus – per mic’s • None susceptible to PZA • Susceptible to macrolides, amikacinimipenem; often quinolones • M. abscessus- need IV drug • 2 and usually 3 drugs preferred • Duration varies; usually at least 1- 11/2 year after sputum smears turn negative • Patients without prescription coverage may not be treatable

  18. Risk Factors for TB • EtOH • Head/Neck, hematologic cancers • Silicosis • HIV - roughly 1 in 14 TB cases have HIV • Medications-transplant, corticosteroid, TNF inhibitors • Gastrectomy • Fe excess, Vit D deficiency • ESRD, DM( Hb A1c> 7) • Celiac Disease • Age

  19. Acid-Fast Staining: Limitations • Non-mycobacterial bacteria can stain positive • Smear-positive respiratory secretion implies contagious individual • Approximately 50% sensitive (sputum) • 3, (and possibly only 1 if suspicion low) sputa rules out contagion but NOT active disease • If AFB (+) respiratory specimen is negative for TB by PCR -TB ruled out, (+) smear due to MOTT

  20. Pathogenesis of TB: Anatomic event Clinical event Calcified lesion (eventually) seen on xray Miliary, endobronchial spread (ARDS, hypersensitivity pneumonitis), late extrapulmonary disease Cavitary pneumonia • Granuloma forms to contain – walls off, creates environment not condusive to growth • Granuloma enlarges, ruptures into bronchus, artery etc. • Liquefaction of granuloma, extracellular growth, inflammatory response lead to necrosis of parenchyma

  21. TB: Miliary, Extra-Pulmonary Disease • Non –specific symptoms may dominate miliary or disseminated TB • Psoas abscess, with or without vertebral osteomyelitis, CNS disease relatively common • May occur with or without active pulmonary disease

  22. Extra- Pulmonary TB* CID 2009,49:1350 * Excludes disseminated or concurrent pulmonary/extra pulmonary disease

  23. Dx. Of TB • PPD – very limited role in dx of active disease due to high rate of false (-) and true - but –unrelated phenomenon • Can help in CNS disease, pericarditis • Definition of (+) PPD depends on circumstances (size, prior tests, host etc.) • Prior BCG – must assume positive skin test could be due to subsequent TB infection • Interferon based assays – M.tb specific immune response to TB proteins, identifies PPD reaction as TB rather than MOTT, more sensitive than PPD for screening, less for active disease

  24. Reading TST Result • Read 48–72 hrs after placement • If HCW returns after >72 hrs, place and read another TST* • Do not let HCWs read their own results • Find and measure induration • Measure diameter of induration across the arm • Do not measure redness

  25. Positive PPD: Interpretation

  26. Criteria for Initiating Respiratory Precautions Patient has symptoms or signs of TB disease Or Patient has documented infectious TB disease and has not completed anti-TB treatment Or HIV and unexplained respiratory sign/symptom

  27. General Points on Tb Rx • INH resistance alone does not affect efficacy of standard 4 drug regimen • Rifabutin preferred over rifampin in HIV • Extra – pulmonary TB Rx 1 year • 2 or more new/active agents for suspected/proven resistance • Steroids for meningitis, pericarditis, ARDS

  28. Rx. of TB Standard regimen for all unless: -Suspected resistance ( foreign born, failed prior Rx) -Pregnancy, coexistent liver disease, drug interaction concerns, intolerance Direct observed Rx when possible Some strains not treatable

  29. Immune Reconstitution Inflammatory Syndrome (IRIS) • Occurs in setting of immune system recovery, usually AIDS and initiation of HAART* • Exuberant or poorly coordinated reactions to antigen, probably larger amount than usually seen in less compromised hosts • Usually mycobacteria, Cryptococcus or CMV retinitis • High fever, lymphadenitis, or paradoxical worsening of primary lesion • Can be worse than initial presentation

  30. Summary • Mycobacteria like lung and lymphatics and weak cell mediated immunity; causing subacute to chronic granulomatous infection • MOTT also like skin and anatomically abnormal lungs, TB likes CNS, vertebrae • Patients with MOTT usually less ill • Size and circumstance matter for PPD • Imaging can’t distinguish MOTT vs TB • Rx requires 2 or more drugs for >6 months, guided by MIC’s

More Related